Reviews/Heart Failure Management/Acetazolamide improves decongestion in acute decompensated heart failure
Adhf · HFM-ADHF-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
One large, high-quality hospital trial tested adding acetazolamide to standard water-pill (loop diuretic) treatment in patients admitted with acute heart failure and fluid overload, and found that more patients were successfully relieved of their congestion [12]. Several further analyses of that same group of 519 patients looked at kidney function, heart pumping strength, bicarbonate and chloride levels, and all pointed the same way [5][8][9][6]. The weaker part of the claim is the salt-excretion (natriuresis) half: the single separate, independent trial was small and found no difference in the total amount of sodium passed in 24 hours, only a better response for each dose of water pill given [2]. So the panel treated the decongestion part as strongly shown and the natriuresis part as less firmly shown. Confidence sits just short of the top tier mainly because almost all the supporting evidence comes from one trial rather than being confirmed by a second large independent study.
The corpus contains one pivotal multicentre double-blind placebo-controlled randomised trial [12] (519 patients) in which successful decongestion occurred in 42.2% of the acetazolamide group versus 30.5% on placebo (risk ratio 1.46, 95% CI 1.17 to 1.82, P<0.001), with higher cumulative urine output and natriuresis. Pre-specified and post-hoc analyses of the same 519 patients show the decongestion effect holds across renal function [5], across left ventricular ejection fraction (OR 1.77, 95% CI 1.18 to 2.63, P=0.005) [8], and across serum chloride [9], and a bicarbonate sub-analysis shows improved decongestive response over the full HCO3 range (P=0.004) [6]. The one independent randomised study [2] (34 patients) found 24h natriuresis similar between arms (264 ± 126 vs 234 ± 133 mmol; P=0.515) but higher loop diuretic efficiency (P=0.048). Together these establish decongestion firmly while leaving absolute natriuresis less secured. The contested point: The evidence divides on the natriuresis half of the claim: ADVOR [12] reports higher natriuresis only descriptively without a quoted effect size or p-value, while the sole independent trial [2] found absolute 24h natriuresis statistically unchanged (P=0.515) and only dose-corrected efficiency improved. It also divides on independence, since six of the seven included sources are ADVOR and [5][6][8][9] are re-analyses of the same 519 patients rather than independent replication.
All 12 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus rests on a single pivotal trial: six of the seven included sources ([5],[6],[7],[8],[9],[12]) are ADVOR, and [5],[6],[8],[9] are re-analyses of the same 519 patients, not independent replication. There is no second large positive trial.
The natriuresis limb is weaker than decongestion: the one independent RCT [2] found absolute 24h natriuresis statistically unchanged (P=0.515), with only dose-corrected efficiency improved, and ADVOR [12] reports higher natriuresis descriptively without a quoted effect size or p-value.
Where it remains uncertain. The only independent randomised trial [2] found absolute 24h natriuresis unchanged (264 ± 126 vs 234 ± 133 mmol; P=0.515) with only loop diuretic efficiency improved, and nearly all corroborating evidence derives from the single ADVOR cohort [5][6][8][9].
Aleatory
The only non-ADVOR randomised comparison [2] enrolled just 34 patients, so its null absolute-natriuresis result (P=0.515) carries wide sampling variability and cannot distinguish a true absent effect from chance.
Epistemic
Six of seven included sources are ADVOR and [5][6][8][9] re-analyse the same 519 patients [12]; the corpus holds no second large positive trial to confirm the effect.
Inferential
The claim rests on decongestion and natriuresis, but death or heart failure rehospitalisation was not improved (HR 1.07, 95% CI 0.78 to 1.48 in [12]), so inference from the intermediate endpoint to clinical benefit is not supported by the corpus.
The load-bearing papers from a corpus of 12, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independent RCT showing absolute natriuresis unchanged, qualifying the natriuresis claim.
“Loop diuretic efficiency, defined as natriuresis corrected for loop diuretic dose, was higher in the group receiving acetazolamide (84 ± 46 vs. 52 ± 42 mmol/mg bumetanide; P = 0.048).”
Panel auditInternal validity: low · scope of inference: AHF patients on loop diuretics specifically selected as high risk for diuretic resistance.Key limitations: tiny sample · comparator is high-dose loop diuretic not placebo · more creatinine rise with acetazolamide
Pre-specified analysis confirming natriuresis/diuresis benefit across renal function.
“Overall, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patients with low eGFR (both P-interaction < .007).”
Panel auditInternal validity: high · scope of inference: ADHF patients with volume overload across the range of baseline eGFR (median 40 mL/min/1.73 m²).Key limitations: subanalysis of ADVOR not independent trial · more worsening renal function with acetazolamide
Sub-analysis confirming decongestion benefit across bicarbonate levels.
“Randomization towards acetazolamide improved decongestive response over the entire range of baseline HCO3- levels (P = 0.004)”
Panel auditInternal validity: high · scope of inference: ADHF patients with volume overload, across baseline bicarbonate levels.Key limitations: subanalysis of ADVOR not independent trial · effect magnified in elevated HCO3 subgroup
This is a baseline-characteristics paper; it states the endpoints studied but reports no treatment results.
Panel auditInternal validity: high · scope of inference: Characterises the elderly real-world AHF population enrolled in ADVOR.Key limitations: no outcome results · design and baseline description only
4 of 12 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A large positive pivotal RCT with consistent sub-analyses strongly supports decongestion, but low evidential independence and a mixed absolute-natriuresis signal hold confidence just below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication of decongestion effect. Almost all positive evidence comes from the single ADVOR cohort [12] with re-analyses [5][6][8][9], so the effect has not been confirmed by an independent study. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second large multicentre double-blind placebo-controlled trial of acetazolamide added to loop diuretics with successful decongestion as the primary endpoint.
Open question: Does adding acetazolamide to loop diuretics increase absolute natriuresis, not just dose-corrected diuretic efficiency? Why it is still open: The only independent trial [2] found 24h natriuresis unchanged (264 ± 126 vs 234 ± 133 mmol; P=0.515) while ADVOR [12] reports higher natriuresis without a quoted effect size.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19